Department of Biomedical Sciences, Colorado State University, Fort Collins, CO 80523-1617, USA.
Mol Pharmacol. 2011 Aug;80(2):267-80. doi: 10.1124/mol.110.070243. Epub 2011 May 4.
At the dimer interface of the extracellular ligand-binding domain of α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptors a hydrophilic pocket is formed that is known to interact with two classes of positive allosteric modulators, represented by cyclothiazide and the ampakine 2H,3H,6aH-pyrrolidino(2,1-3',2')1,3-oxazino(6',5'-5,4)benzo(e)1,4-dioxan-10-one (CX614). Here, we present structural and functional data on two new positive allosteric modulators of AMPA receptors, phenyl-1,4-bis-alkylsulfonamide (CMPDA) and phenyl-1,4-bis-carboxythiophene (CMPDB). Crystallographic data show that these compounds bind within the modulator-binding pocket and that substituents of each compound overlap with distinct moieties of cyclothiazide and CX614. The goals of the present study were to determine 1) the degree of modulation by CMPDA and CMPDB of AMPA receptor deactivation and desensitization; 2) whether these compounds are splice isoform-selective; and 3) whether predictions of mechanism of action could be inferred by comparing molecular interactions between the ligand-binding domain and each compound with those of cyclothiazide and CX614. CMPDB was found to be more isoform-selective than would be predicted from initial binding assays. It is noteworthy that these new compounds are both more potent and more effective and may be more clinically relevant than the AMPA receptor modulators described previously.
在 α-氨基-3-羟基-5-甲基异恶唑-4-丙酸(AMPA)受体的细胞外配体结合域的二聚体界面处,形成了一个亲水口袋,已知该口袋与两类正变构调节剂相互作用,以噻嗪环和氨卡林 2H,3H,6aH-吡咯烷并[2,1-3',2']1,3-恶嗪[6',5'-5,4]苯并[e]1,4-二恶烷-10-酮(CX614)为代表。在这里,我们提出了两种新型 AMPA 受体正变构调节剂,苯基-1,4-双烷基磺酰胺(CMPDA)和苯基-1,4-双羧基噻吩(CMPDB)的结构和功能数据。晶体学数据表明,这些化合物结合在调节剂结合口袋内,并且每个化合物的取代基与噻嗪环和 CX614 的不同部分重叠。本研究的目的是确定 1)CMPDA 和 CMPDB 对 AMPA 受体去激活和脱敏的调节程度;2)这些化合物是否对剪接异构体具有选择性;3)通过比较配体结合域与每种化合物之间的分子相互作用与噻嗪环和 CX614 的分子相互作用,是否可以推断出作用机制的预测。发现 CMPDB 比初始结合测定更具异构体选择性。值得注意的是,这些新化合物不仅更有效,而且可能比以前描述的 AMPA 受体调节剂更具临床相关性。